J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
The detection of minimal lymphoma by molecular and combined culture-molecular methods.
TL;DR: The substantial frequency of failure of obtaining tumour‐specific IgH CDRIII sequences in paraffin‐embedded B‐NHLs argues for the storage of frozen tumour samples for possible molecular studies.
Journal ArticleDOI
Clinical outcome of peripheral blood stem cell support
Anne Kessinger,James O. Armitage,Philip J. Bierman,Michael R. Bishop,Shantaram S. Joshi,Elizabeth C. Reed,Graham Sharp,James E. Talmadge,Julie M. Vose +8 more
TL;DR: Patients who receive peripheral stem cell transplantation may experience an improved progression-free survival after high-dose therapy when compared with similar patients who receive autologous bone marrow transplantation.
Journal ArticleDOI
A Phase I Dose Expansion Cohort Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), An Orally Administered PI3K/mTOR Inhibitor, in Patients with Lymphoma
Kyriakos P. Papadopoulos,Pau Abrisqueta,Glenda Chambers,Drew W. Rasco,Amita Patnaik,Josep Tabernero,Kanya Rajangam,Kevin Rockich,Coumaran Egile,Adrianne Kelly,Yi Xu,Joanne Lager,Julie M. Vose +12 more
TL;DR: In this phase 1 dose-expansion cohort study in lymphoma, SAR245409 was generally well tolerated and showed promise in several lymphoma subtypes, with 1 showing robust pharmacodynamic modulation of PI3K and ERK pathway signaling.
Journal ArticleDOI
Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma.
Julie M. Vose,Philip J. Bierman,Fausto R. Loberiza,Charles A. Enke,Jordan Hankins,Robert G. Bociek,Wing C. Chan,Dennis D. Weisenburger,James O. Armitage +8 more
TL;DR: The PFS and OS were encouraging in this group of chemotherapy-sensitive persistent, relapsed, or high-risk patients with DLBCL and a follow-up phase III trial with 131-Iodine tositumomab/BEAM vs rituximab /BEAM was planned based on this information.
Journal ArticleDOI
Novel therapy for therapy-resistant mantle cell lymphoma: multipronged approach with targeting of hedgehog signaling.
Ganapati V. Hegde,Tara M. Nordgren,Corey M. Munger,Amit K. Mittal,Philip J. Bierman,Dennis D. Weisenburger,Julie M. Vose,J. Graham Sharp,Shantaram S. Joshi +8 more
TL;DR: An in vivo model of therapy‐resistant MCL is developed by transplanting a patient‐derived MCL cell line into NOD/SCID mice followed by treatment with combination chemotherapy to reduce tumor burden combined with GLI‐antisense oligonucleotides or bortezomib, a proteosome inhibitor, to target therapy‐ resistant MCL cells that remained after chemotherapy.